Improved Blood Flow
L-arginine may enhance circulation, potentially benefiting conditions like high blood pressure, erectile dysfunction, and peripheral artery disease. Studies suggest modest improvements in blood pressure and exercise capacity in some populations.
Heart Health
It may reduce symptoms of angina and improve vascular function, though evidence is mixed and not conclusive for preventing heart disease.
Erectile Dysfunction
Some research indicates L-arginine, especially when combined with supplements like pycnogenol, can improve mild to moderate erectile dysfunction by enhancing blood flow.
Exercise Performance
Limited evidence suggests it may boost exercise tolerance, particularly in untrained individuals or those with cardiovascular issues, but results vary.
Wound Healing
L-arginine may support tissue repair and immune function, potentially aiding recovery in burn patients or those with chronic wounds.
Immune Support
It may enhance immune response, particularly in specific medical contexts, but more research is needed.
Nitric Oxide Synthesis
L-arginine is converted into nitric oxide by the enzyme nitric oxide synthase (NOS) in endothelial cells, macrophages, and other tissues. This reaction also produces L-citrulline as a byproduct. Nitric oxide acts as a vasodilator, relaxing smooth muscle cells in blood vessel walls, which improves blood flow and reduces vascular resistance.
Vascular Effects
By increasing NO levels, L-arginine promotes vasodilation, which enhances blood circulation, lowers blood pressure, and improves oxygen delivery to tissues. This is particularly relevant in conditions like hypertension, erectile dysfunction, or atherosclerosis, where impaired NO production is a factor.
Cellular and Metabolic Role
L-arginine supports protein synthesis and serves as a building block for proteins, aiding tissue repair and growth. It stimulates the release of hormones like insulin and growth hormone, which may enhance metabolism and tissue recovery. In immune cells, L-arginine supports the production of NO, which has antimicrobial properties and modulates immune responses.
Study: A randomized, double-blind, placebo-controlled trial involving 101 patients with severe COVID-19. Patients received oral L-arginine (dose not specified in interim analysis) or placebo alongside standard therapy.
Findings: L-arginine significantly reduced hospital stay (median 25 days vs. 46 days for placebo, p < 0.0001) and respiratory support needs at 10 days (71.1% of L-arginine patients vs. 44.4% placebo, p < 0.01), but not at 20 days. No serious treatment-related adverse events were reported.
Link: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00383-8/fulltext
Study: A double-blind, randomized, placebo-controlled trial with 98 patients (51 L-arginine, 47 placebo) with vasculogenic erectile dysfunction (ED). Patients received 6 g/day oral L-arginine or placebo for 3 months. Outcomes measured included the International Index of Erectile Function (IIEF-6) score and penile blood flow via duplex ultrasonography.
Findings: L-arginine significantly improved IIEF-6 scores (p < 0.0001) in the overall cohort and subgroups with mild-moderate (p < 0.0001) and severe ED (p = 0.007). Penile blood flow (peak systolic velocity) increased significantly in mild-moderate ED (p < 0.0001) but not severe ED. 74% of patients improved ED severity, with 24% achieving normal erectile function.
Link: https://link.springer.com/article/10.1007/s40618-021-01704-3
Study: A double-blind, randomized, placebo-controlled trial with 56 healthy male athletes in Iran, aged 16–35, receiving 2 g/day oral L-arginine or placebo (maltodextrin) for 45 days. Outcomes included lipid profiles, blood glucose, and blood pressure.
Findings: L-arginine significantly reduced triglyceride levels (p = 0.04) but had no significant effect on total cholesterol, LDL, HDL, blood glucose, or blood pressure. The study suggests low-dose L-arginine may improve specific cardiovascular risk factors in healthy individuals.
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519277/
Study: A prospective, open-label, single-arm trial with 20 amyotrophic lateral sclerosis (ALS) patients (40% female, mean age 62) receiving 15 g/day oral L-arginine hydrochloride for 90 days. Primary outcome was safety; secondary outcomes included nutritional status and ALS Functional Rating Scale (ALSFRS) scores.
Findings: L-arginine was well-tolerated, with no serious treatment-related adverse events. Minor adverse events (30% of patients) included elevated creatine kinase, liver function abnormalities, and glucose tolerance issues. No significant changes in body weight, BMI, or ALSFRS scores were observed, suggesting safety but limited efficacy for ALS progression.
Link: https://www.nature.com/articles/s41598-024-80658-0
Study: A meta-analysis of 22 randomized, placebo-controlled trials with 30 effect sizes, examining oral L-arginine’s impact on blood pressure in adults. Doses ranged from 4–30 g/day, with intervention durations ≥4 days.
Findings: L-arginine significantly reduced systolic blood pressure (WMD = -6.40 mmHg, p < 0.001) and diastolic blood pressure (WMD = -2.64 mmHg, p < 0.001) across normotensive and hypertensive groups, regardless of study duration, sex, or BMI. Doses ≥4 g/day were effective for systolic blood pressure, with greater diastolic reductions in females.
Link: https://pubmed.ncbi.nlm.nih.gov/36297080/
Study: A multicenter, randomized, double-blind, placebo-controlled trial with 153 patients post-ST-segment elevation myocardial infarction, receiving 3 g L-arginine or placebo three times daily for 6 months. Primary outcome was left ventricular ejection fraction; secondary outcomes included vascular stiffness and clinical events.
Findings: L-arginine showed no significant improvement in ejection fraction or vascular stiffness compared to placebo. A trend toward reduced pulse wave velocity was noted, but the study suggested potential harm in post-myocardial infarction patients, with higher mortality in the L-arginine group (not statistically significant).
Link: https://jamanetwork.com/journals/jama/fullarticle/202169
Study: A randomized, double-blind, crossover trial with 15 patients with moderate to severe heart failure, receiving 5.6–12.6 g/day oral L-arginine or placebo for 6 weeks each. Outcomes included forearm blood flow during exercise, endothelin levels, and functional status.
Findings: L-arginine significantly increased forearm blood flow during exercise (5.1±2.8 to 6.6±3.4 mL·min⁻¹·dL⁻¹, p < 0.05) and reduced endothelin levels (1.9±1.1 to 1.5±1.1 pmol/L, p < 0.05). Patients reported improved quality of life and walked farther in a 6-minute walk test, suggesting benefits for heart failure symptoms.
Link: https://www.ahajournals.org/doi/10.1161/01.CIR.93.12.2135